<IPO>AI Drug Startup Insilico Medicine Reportedly Plans to Relaunch HK IPO w/ US$1B+ Valuation
Insilico Medicine Inc., an AI-driven drug discovery startup, is contemplating rebooting its Hong ...
Insilico Medicine Inc., an AI-driven drug discovery startup, is contemplating rebooting its Hong Kong IPO plans following a new round of financing, Bloomberg reported. The company is anticipated to pursue a listing with a valuation exceeding USD1 billion.
In January this year, Insilico Medicine wrapped up a Series E funding round led by Value Partners Group, seizing approximately USD110 million. The round wooed investors including Warburg Pincus, OrbiMed Advisors, and Eli Lilly.
Insilico Medicine had previously submitted Main Board listing applications to the Hong Kong Stock Exchange in June 2023 and March 2024, with Morgan Stanley and CICC serving as joint sponsors.
Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.
